US EditionTrump announces deals with Eli Lilly, Novo Nordisk to slash weight loss drug prices, offer some Medicare coverage
The deal lowers monthly costs to as little as $50 copays for Medicare patients and expands coverage to about 10% of Medicare beneficiaries, officials said.
- President Trump announced deals with Eli Lilly and Novo Nordisk to cut prices of obesity drugs for Medicare and Medicaid beneficiaries in 2026.
- The deals will offer obesity treatments directly to consumers at discounted prices on a website called TrumpRx.gov starting in January.
- Certain Medicare patients will pay $50 per month for approved GLP-1 drugs, and upcoming obesity pills from Lilly and Novo Nordisk will cost $145 per month initially.
131 Articles
131 Articles
President Donald Trump said that his administration has concluded an agreement to reduce the costs of drugs for the GLP-1, Wegovy and Zepbund, respectively — a measure that could significantly extend access to these extremely popular drugs, although some details of the agreement are still unclear, writes nbcnews.com.
Eli Lilly, Novo Nordisk Make Weight-Loss Drugs More Affordable Via Medicare, Medicaid, TrumpRx - Novo Nordisk (NYSE:NVO), Eli Lilly (NYSE:LLY)
President Donald Trump on Thursday announced agreements with Eli Lilly and Co. (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) to significantly reduce prices for their GLP-1-based obesity and diabetes drugs. The deals will also expand Medicare and Medicaid coverage for these high-demand treatments beginning in mid-2026. In September, Trump announced the first agreement with a major pharmaceutical company, Pfizer Inc. (NYSE:PFE), to bring American dru…
Trump administration announces deal to lower weight loss drug prices for many Americans
Andrew Harnik/Getty Images (WASHINGTON) — The Trump administration announced deals on Thursday with pharmaceutical giants Novo Nordisk and Eli Lilly that would lower the cost of GLP-1 drugs for many Americans, including those on Medicare. The administration negotiated how much both the government and consumers would pay for the drugs, which are used to treat obesity and diabetes as well as other cardiometabolic conditions. As soon as the public-…
Washington, Nov 6 (EFE).- U.S. President Donald Trump announced Thursday an agreement to reduce the price of weight loss drugs, such as Ozempic and Wegovy, and increase the coverage of these products in Medicare and Medicaid health programs. The pact, reached with pharmaceutical companies Eli Lilly and Novo Nordisk, seeks to make these drugs more accessible that have become popular in recent years among people seeking to lose weight, but that, i…
Trump unveils deals to lower costs of some weight-loss drugs
US President Donald Trump announced deals Thursday with pharmaceutical giants Eli Lilly and Novo Nordisk to lower the prices of some popular weight-loss drugs, in exchange for relief from threatened tariffs.
Coverage Details
Bias Distribution
- 60% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
